Multiple sclerosis (MS) affects an estimated 2.5 million people worldwide. It is the most widespread disabling neurological condition of young adults. MS develops at any age, but most people are diagnosed between ages of 20 and 50. There is no single test for the diagnosis of multiple sclerosis. Additionally, different stages of MS cannot be determined in advance. The first step in diagnosing the disease involves a careful study of a patient’s medical history combined with a thorough physical and neurologic examination, while ruling out other possible causes of neurodegenerative symptoms.
MS is further classified into relapsing, remitting, and progressive. Eighty-five percent of MS patients will be initially diagnosed with relapsing remitting multiple sclerosis (RRMS). Of those, nearly 50% will have transition to secondary progressive multiple sclerosis (SPMS) within 10 years of the initial diagnosis. Currently, the transition to SPMS is diagnosed retrospectively based on clinical presentation and progression due to the lack of a reliable diagnostic test. The challenge for physicians has been the timely diagnosis of MS progression in order to make clinical treatment decisions aimed at retarding progression of the disease.
1 National Multiple Sclerosis Society. Vaccination; Dilokthornsakul, P., et al., Multiple sclerosis prevalence in the United States commercially insured population. Neurology, 2016. 86(11): p. 1014-21.
(in dev.) numares develops a diagnostic test that reliably identifies the emerging transition from RRMS to SPMS by detecting alterations in metabolite biomarker constellations. In collaboration with the University of Oxford, numares is evaluating metabolite constellations of biomarkers to monitor relapsing-remitting multiple sclerosis (RRMS) patients for the transition to the progressive form (secondary-progressive MS, SPMS). An early detection of the transition would improve clinical decision making with early therapy intervention.
More information on the AXINON® IVD System
The novel diagnostic test will be performed on the AXINON® System which produces high-quality, standardized NMR spectra based on numares’ Magnetic Group Signaling (MGS®) technology.
The combination of MGS® with the AXINON® technology platform allows for test-specific spectral analysis with highly-reproducible results. The system is easy to use with one-step sample preparation with ready-to-use reagents requiring minimal operator interaction. The test system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.
To date, more than 2 million tests have been performed worldwide using the numares’ technology platform.
For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.